Call (415) 636-9700 Phone Mon–Fri 8a–8p · Sat 9a–5p

What If TMS Doesn’t Work — or You Had to Stop Early?

TMS Therapy · Hayward, CA

TMS is generally well tolerated, but that does not mean every patient has an easy course. Some people feel scalp or stimulation-site discomfort, tension-type headaches, nausea, lightheadedness, or fatigue, and a smaller number notice anxiety or irritability.[3] So if TMS felt bad for you, or if it simply did not help, the next step is not to distrust all of medicine. The next step is to tell your provider clearly and quickly.

Persistent side effects need follow-up

If anxiety, irritability, agitation, insomnia, headaches, mood worsening, or emotional instability continue after TMS, your provider needs to know. That does not mean you did something wrong. It means your nervous system may not have responded well to that protocol, intensity, target, or treatment pace. In some cases a clinician may adjust the protocol; in others, pausing or stopping may be the safer move.[3]

This is not something to manage silently. TMS works on brain circuits, and how you respond to it is clinically important information.

Sometimes the brain needs stabilization first

After a difficult TMS experience, some patients need a period of stabilization before jumping straight into another intensive treatment. That does not mean doing nothing. It may mean getting sleep steadier, easing back on substances that worsen mood or anxiety, keeping therapy consistent, tracking symptoms, and letting the nervous system settle while your provider reassesses the next step. Think of it less as giving up and more as letting the brain get stable enough to make the next decision wisely.

What to actually expect

What a TMS course really looks like.

Knowing the shape of a standard course helps you read your own progress fairly — including the fact that improvement can build slowly, and partial response is useful information, not a failure.
  What it typically means
How often About 5 sessions a week
How long Roughly 4 to 6 weeks of treatment
Total sessions Around 30 to 36 in a standard course
How response shows up It can build gradually, not all at once
Partial response Is information your provider can use — not a failure
Standard rTMS course for depressionexxceedwellness.com

What may come next

If TMS did not help, or if you had to stop early, the next step depends on what happened. If there was no benefit, your provider may recheck the diagnosis, medication history, depression subtype, anxiety level, sleep, trauma, bipolar symptoms, substance use, or medical factors. If there was partial benefit, a modified protocol or maintenance plan may be considered — a standard course runs about five sessions a week for four to six weeks, and response can build gradually, so partial response is useful information rather than a failure.[1][2] If the side effects were the problem, the plan may need to move away from TMS entirely.[4]

Other options may include medication adjustment, augmentation, psychotherapy changes, behavioral activation, or trauma-focused therapy. For more severe or treatment-resistant depression, your provider may discuss SPRAVATO (esketamine) — FDA-approved for adults with treatment-resistant depression and given in a monitored clinical setting[5] — or, in severe cases, ECT, which remains one of the most effective treatments for severe depression.[6]

If TMS underwhelmed or you stopped early

Next steps to talk through.

A setback is information. The point now is to stabilize, report honestly, and choose the next move with more precision — these are the options a careful provider weighs with you.
  • Re-evaluate — recheck the diagnosis, medication history, depression subtype, anxiety, sleep, trauma, bipolar symptoms, and substance use.
  • Optimize the protocol — if there was partial benefit, a modified protocol or maintenance plan may help.
  • Stabilize first — steadier sleep, fewer mood-worsening substances, and consistent therapy while the nervous system settles.
  • Switch modality — medication adjustment, augmentation, behavioral activation, or trauma-focused therapy.
  • Consider SPRAVATO — esketamine, FDA-approved for treatment-resistant depression, given in a monitored clinical setting.
  • ECT for severe cases — one of the most effective options when depression is severe or urgent.
Save · review before your next appointmentexxceedwellness.com

The takeaway

A difficult or unsuccessful TMS course does not mean you are untreatable. It means this specific treatment, protocol, or timing may not have been the right fit — and that information matters. The goal now is to stabilize, report symptoms honestly, reassess the map, and choose the next step with more precision. A treatment setback is not the end of care. It is data for a better plan.

Talk it through · Exxceed Wellness

TMS didn’t work, or you stopped early?

That’s a starting point, not a dead end. We’ll reassess the map together — what happened, what your symptoms are doing now, and which next step fits you with more precision.

Book a consultation

Nefretiri Abat, JD, PMHNP-BC · Hayward, CAexxceedwellness.com

References

  1. Perera T, George MS, Grammer G, et al. The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 2016;9(3):336-346. PMID: 27090022 · doi:10.1016/j.brs.2016.03.010.
  2. McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):16cs10905. PMID: 28541649 · doi:10.4088/JCP.16cs10905.
  3. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120(12):2008-2039. PMID: 19833552 · doi:10.1016/j.clinph.2009.08.016.
  4. U.S. Food and Drug Administration / eCFR. 21 CFR 882.5805 — Repetitive transcranial magnetic stimulation system. ecfr.gov (21 CFR 882.5805).
  5. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray — Highlights of Prescribing Information. Revised 2025. accessdata.fda.gov (211243s019lbl.pdf). (J&J standalone monotherapy approval for treatment-resistant depression announced January 21, 2025.)
  6. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799-808. PMID: 12642045 · doi:10.1016/S0140-6736(03)12705-5.

Comments are closed